PRE

NEUTRAL

$17.83 Live

Prenetics Global Limited · NASDAQ

Target $31.25 (+75.3%)

$4.15 52W Range $23.63

PRE Prenetics Global Limited - Fundamental Analysis

NEUTRAL

Console Chart News

PRE Stock | Fundamental Analysis & Investment Insights

NASDAQ • Healthcare • Diagnostics & Research

Current Price Live

$17.83

Analyst Target

$31.25

+75.3% Upside

52W High

$23.63

52W Low

$4.15

Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 18, 2026

Market cap

$300.86M

P/E

N/A

ROE

-31.8%

Profit margin

-63.1%

Debt/Equity

0.01

Dividend yield

N/A

AI Analysis

AI-powered fundamental assessment

Confidence

75%

Prenetics Global Limited presents a high-risk, high-reward profile characterized by explosive revenue growth (248.6% YoY) contrasted with deep operational losses. The Piotroski F-Score of 4/9 indicates a stable but not strong financial position, while the absence of an Altman Z-Score is mitigated by an exceptionally low Debt/Equity ratio (0.01) and strong liquidity (Current Ratio 3.01). While analysts maintain a 'strong_buy' rating with a target of $31.25, the 0/100 technical trend and low insider sentiment (40/100) suggest significant near-term headwinds despite the long-term growth trajectory.

Key Strengths

Hyper-growth revenue trajectory (248.6% YoY, 567.66% Q/Q)

Pristine balance sheet with negligible debt (Debt/Equity 0.01)

Strong liquidity position with a Current Ratio of 3.01

Healthy Gross Margins (52.98%) indicating a viable core product

Strong analyst consensus with a significant upside to target price ($31.25)

Key Risks

Severe lack of profitability (Profit Margin -63.13%)

Bearish technical trend (0/100) indicating negative price momentum

Low insider sentiment (40/100) suggesting lack of internal confidence

High volatility as evidenced by the 52-week range ($4.15 - $23.63)

Dependence on future scaling to offset high operating expenses

AI Fair Value Estimate

Based on comprehensive analysis

$24.5

+37.4% above current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall

Moderate

Value

Future

Past

Health

Dividend

AI Verdict

Speculative Growth

Key drivers: Revenue Growth, Balance Sheet Strength, Negative Net Income

Confidence

80%

Value

30/100

Trades at a premium based on sales (P/S 3.26) rather than earnings.

Positives

Reasonable Price/Book (1.64)

Watchpoints

Negative P/E
No Graham Number due to lack of earnings

Future

90/100

Growth rates are significantly above sector averages.

Positives

Exceptional YoY and Q/Q revenue growth
Improving EPS trajectory

Watchpoints

Forward P/E remains negative

Past

45/100

Recent momentum is strong, but long-term history is poor.

Positives

Massive 1Y price recovery (+344.6%)

Watchpoints

Poor 5Y performance (-84.7%)
Inconsistent earnings surprises

Health

70/100

Strong solvency and liquidity offset the lack of profitability.

Positives

Very low debt
High current and quick ratios

Watchpoints

Piotroski F-Score of 4/9 is only mediocre

Dividend

0/100

Company is in a growth phase and does not distribute capital.

Positives

No standout positives identified.

Watchpoints

No dividend paid
0/100 strength score

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price

$17.83

Analyst Target

$31.25

Upside/Downside

+75.3%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for PRE and closest competitors.

Updated 2026-04-17

Company	5Y	3Y	1Y	6M	1M	1W
PRE Prenetics Global Limited Primary	-84.7%	+41.9%	+344.6%	+18.9%	-12.8%	+0.6%
ACIU AC Immune SA Peer	-62.7%	+31.1%	+31.1%	+24.1%	-0.5%	+8.1%
ANL Adlai Nortye Ltd. Peer	-47.0%	-47.0%	+247.2%	+345.4%	-14.4%	-10.8%
CV CapsoVision, Inc. Peer	+79.0%	+79.0%	+79.0%	+33.0%	+22.8%	-14.1%
AMRN Amarin Corporation plc Peer	-88.3%	-51.5%	+87.1%	+2.2%	+1.5%	+9.1%

PRE

Prenetics Global Limited

Primary

-84.7%

+41.9%

+344.6%

+18.9%

-12.8%

+0.6%

ACI

AC Immune SA

Peer

-62.7%

+31.1%

+24.1%

-0.5%

+8.1%

ANL

Adlai Nortye Ltd.

Peer

-47.0%

+247.2%

+345.4%

-14.4%

-10.8%

CapsoVision, Inc.

Peer

+79.0%

+33.0%

+22.8%

-14.1%

AMR

Amarin Corporation plc

Peer

-88.3%

-51.5%

+87.1%

+2.2%

+1.5%

+9.1%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

N/A

-26.22

N/A

1.64

3.26

2.32

-6.5

$300.86M

Profitability

Profit margins and return metrics

Profit Margin -63.13%

Operating Margin -33.27%

Gross Margin 52.98%

ROE -31.79%

ROA -11.02%

Growth

Revenue and earnings growth rates

Revenue Growth +248.6%

Earnings Growth N/A

Q/Q Revenue Growth +567.66%

Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity

0.01

Low debt

Current Ratio

3.01

Strong

Quick Ratio

2.76

Excellent

Cash/Share

$4.57

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q3 2025

Revenue

$0.0B

Gross Margin

59.5%

Op. Margin

-27.8%

Net Margin

-31.4%

Total Assets

$0.2B

Liabilities

$0.0B

Equity

$0.2B

Debt/Equity

0.22x

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-12

$N/A

2026-02-18

$-0.19

+63.2% surprise

2025-11-10

$-0.53

+3.6% surprise

2025-09-12

$-0.94

-32.4% surprise

Healthcare Sector Comparison

Comparing PRE against 418 companies in the Healthcare sector (24 bullish, 134 neutral, 260 bearish)

Return on Equity (ROE)

-31.79%

This Stock

-101.05%

Sector Avg

-68.5% (Below Avg)

Profit Margin

-63.13%

This Stock

-13.75%

Sector Avg

+359.0% (Superior)

Debt to Equity

0.01

This Stock

3.24

Sector Avg

-99.7% (Less Debt)

Revenue Growth

248.6%

This Stock

121.5%

Sector Avg

+104.6% (Fast Growth)

Current Ratio

3.01

This Stock

4.55

Sector Avg

-33.8% (Weaker)

Similar Companies

Peer comparison within the same industry

Company	AI Rating	Market Cap	P/E	ROE	Profit Margin	Price
PRE Prenetics Global Limited	NEUTRAL	$300.86M	-	-31.8%	-63.1%	$17.83
ACIU AC Immune SA	BEARISH	$303.31M	-	-74.6%	-%	$3.02	Compare
ANL Adlai Nortye Ltd.	BEARISH	$293.36M	-	-139.0%	-%	$7.95	Compare
CV CapsoVision, Inc.	BEARISH	$312.24M	-	-184.9%	-186.8%	$6.26	Compare
AMRN Amarin Corporation plc	BEARISH	$319.13M	-	-8.2%	-18.2%	$15.34	Compare

PRE Prenetics Global Limited

NEUTRAL

Mkt Cap

$301M

P/E

ROE

-31.8%

Price

$17.83

Compare with PRE

ANL Adlai Nortye Ltd.

Compare with PRE

Compare with PRE

AMRN Amarin Corporation plc

Compare with PRE

Wall Street Analysts

Professional analyst ratings and price targets

Consensus

STRONG_BUY

4 analysts

Lake Street

2026-03-16

init

Buy

Cantor Fitzgerald

2025-10-29

Maintains

Overweight Overweight

Past News Coverage

Recent headlines mentioning PRE from our newsroom.

Newest → oldest

Back to All Stocks

TradingGPT V2 Copilot

Fundamentals • Valuation • Risk

Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends

PRE

PRE Prenetics Global Limited - Fundamental Analysis

At a glance

AI Analysis

Key Strengths

Key Risks

Performance Snowflake

Stock Price & Analyst Targets

Multi-Horizon Performance vs Peers

Historical Performance Trends

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Valuation Metrics

Profitability

Growth

Financial Health

Financial Statement Flow

Quarterly Earnings History

Healthcare Sector Comparison

Similar Companies

Wall Street Analysts

Past News Coverage

Wait — Don't Miss Out!